UBS’s Standard BioTools LAB Stock Holding History

UBS’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$39K	Sell	1,600 -3,915	-71%	-$110K	﹤0.01%	7133
2014 Q2	$162K	Buy	5,515 +1,365	+33%	+$43.7K	﹤0.01%	5378
2014 Q1	$183K	Sell	4,150 -33,187	-89%	-$1.46M	﹤0.01%	5292
2013 Q4	$1.43M	Buy	37,337 +31,491	+539%	+$928K	﹤0.01%	3159
2013 Q3	$128K	Sell	5,846 -10,842	-65%	-$213K	﹤0.01%	5734
2013 Q2	$291K	Buy	+16,688	New	+$293K	﹤0.01%	4679

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS's LAB Position: Q3 2014 in Review

UBS reduced its Standard BioTools (LAB) stake by 71% in Q3 2014, selling an estimated $110K and leaving 1,600 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #7133.

UBS first reported a position in LAB in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.43M in Q4 2013. 99 funds tracked by Wall St. Rank hold LAB as of Q3 2014.

UBS held 1,600 shares of Standard BioTools worth $39K as of Q3 2014.
UBS sold 3,915 Standard BioTools shares in Q3 2014, an estimated $110K.
Standard BioTools made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7133 holding.
UBS first reported a position in Standard BioTools in Q2 2013 and has held it in 6 quarters since.
UBS's Standard BioTools position peaked at $1.43M in Q4 2013.
99 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.